Shire Builds Confidence In $20bn Revenue Target
Shire's first investor R&D day after its major acquisition of Baxalta earlier this year saw management keen to "bring confidence to the $20bn revenue target figure that we have stated," said CEO Flemming Ornskov. Shire's hemophilia focus, in particular, is facing some scrutiny.
You may also be interested in...
Emicizumab Data Has Shire And Novo Looking Over Their Shoulders
Positive data from the HAVEN 1 Phase III study of Genentech's emicizumab put pressure on the hemophilia franchises of both Shire and Novo Nordisk.
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.
Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations
Launched in August for dry eye disease, Xiidra already has seen nearly 65,000 prescriptions written and has captured 16% market share in the US. Overall quarterly sales came in below Wall Street expectations for Shire, but the firm says it was a strong quarter of execution.